The financing will support a Phase 2 clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase 1b trial in melanoma in combination with TILs and other Phase 1b trials, the company states.

“We’re excited to have already opened the first site in the USA and are looking forward to dosing our first patients soon and opening at least five more sites this year,” says Tiltbio’s founder and CEO, Akseli Hemminki. “Ovarian cancer continues to be an unmet medical need despite recent therapies being approved. There are no oncolytic viruses or checkpoint inhibitors currently approved for use in this indication.”

Data from its Phase 1a clinical trial

The company recently published data from its Phase 1a clinical trial (PROTA) in platinum-resistant ovarian cancer. The data showed that treatment was well tolerated with an excellent safety profile and promising efficacy observed in some patients. Disease control was achieved in 64% of evaluable patients (9/14) while the overall response rate was 20% at the highest dose level. Median progression-free survival and overall survival were 98 and 190 days respectively. Interim results from ongoing Phase 1b trials are expected to read out in H2 2026.

TILT-123

TILT-123 (Igrelimogene litadenorepvec), an oncolytic adenovirus armed with tumor necrosis factor (TNF) and interleukin-2 (IL-2), is designed to enhance the efficacy of T-cell therapies and immune checkpoint blockade. Tiltbio has a collaboration with MSD investigating TILT-123 in combination with KEYTRUDA (pembrolizumab) in ovarian cancer (NCT05271318).